We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Biopharma

Biopharma

Stay up to date on the topics that matter to you

Trending News

An elderly man having a vaccine.

What Happens to the Human Body After 200 Vaccines?

T-cells.

Immune System Involvement in Dermatomyositis Revealed

Protein structure.

Protein That Controls CAR T-Cell Longevity Identified

Researchers Decode the Mechanism of Action of Hepatitis B and D Virus Inhibitor

Language Model Reads the Genome and Designs More Effective mRNA Vaccines

Experimental Pancreatic Cancer Vaccine May Elicit Lasting Immune Response

News

Trimel Pharmaceuticals Corporation Completes Patient Enrollment of CompleoTRT Phase III Safety Cohort

The Phase III study represents the final stage of product development prior to Trimel anticipated submission of a New Drug Application (NDA) to the FDA for marketing approval in the United States.

Edison Expands European Biotech Presence

The UK-based independent equity research firm increases European biotech presence by announcing the initiation of research coverage on Transgene, a French immunotherapy drug discovery and development company.

Stem Cell Technologies Finding a Larger Market, Report Says

The market will rise to over $700 million this year, and given some positive trends could reach over one billion dollars, according to healthcare market research publisher Kalorama Information.

Waters and Tecan Sign Agreement for Clinical Assay Platform

The agreement will address the growing need for greater efficiencies and throughput that can be obtained with the automation of routine clinical laboratory assays.

Antares Pharma Enters Licensing Agreement with Daewoong Pharmaceuticals Co. Ltd.

Antares announced that it has licensed exclusively its Oxybutynin Gel 3% to Daewoong Pharmaceuticals, for marketing in South Korea. Antares will receive undisclosed upfront payments, regulatory milestones and sales based milestones, as well as royalties on net sales for the product.

MAP Pharmaceuticals Appoints W. James O'Shea to Board of Directors

Mr. O'Shea brings to the Board 35 years of healthcare industry experience in product commercialization and operations as well as marketing and medical affairs.

Valeant Pharmaceuticals Increases Proposed Price for Acquisition of ISTA Pharmaceuticals Inc

The company announced that it has increased from $6.50 to $7.50 per share in cash the proposed price of its previously announced offer to acquire ISTA Pharmaceuticals Inc. Valeant has expressed disappointment that the Board of Directors and management of ISTA have not been willing to meaningfully engage with Valeant.

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301

The company announced that dosing was initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects. The study is being conducted in collaboration with Rockefeller University.

Omni Bio Announces Progress of BioMimetix Pharmaceutical for Cancer and Radiation Therapy

The clinical-stage biopharmaceutical company announced a progress report of a new antioxidant molecule being developed by BioMimetix Pharmaceutical, Inc., of which Omni Bio is currently the largest shareholder.

Constellation Pharmaceuticals and Genentech Enter Broad Epigenetics Drug Discovery Collaboration

The partnership aims to discover and develop innovative treatments for cancer and other serious diseases.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter